Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD

Gut

Volumn 64, Issue 3, 2015, Pages 447-458

  De Preter, Vicky ^a   Machiels, Kathleen ^a   Joossens, Marie ^a,b,c   Arijs, Ingrid ^a   Matthys, Christophe ^d   Vermeire, Severine ^a   Rutgeerts, Paul ^a   Verbeke, Kristin ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEPTANOIC ACID; HEXANOIC ACID; MEDIUM CHAIN FATTY ACID; NONANOIC ACID; OCTANOIC ACID; STYRENE; UNCLASSIFIED DRUG; VALERIC ACID; FATTY ACID; HEXANOIC ACID DERIVATIVE; OCTANOIC ACID DERIVATIVE; VALERIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE ASSOCIATION; FATTY ACID ANALYSIS; FECES ANALYSIS; FEMALE; HUMAN; ILEITIS; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOMICS; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; ADOLESCENT; CASE CONTROL STUDY; CHEMISTRY; FECES; INFLAMMATORY BOWEL DISEASES; METABOLISM; MICROFLORA; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CAPROATES; CAPRYLATES; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FATTY ACIDS; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MICROBIOTA; MIDDLE AGED; POUCHITIS; SENSITIVITY AND SPECIFICITY; VALERATES; YOUNG ADULT;

EID: 84922390026     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306423     Document Type: Article

References (60)

1. Packey CD, Sartor RB. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis 2009; 22:292-301.
2. Rutgeerts P, Geboes K, Peeters M., et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338:771-4.
3. Braun A, Treede I, Gotthardt D., et al. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009; 15:1705-20.
4. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126:1620-33.
5. Png CW, Linden SK, Gilshenan K.S., et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 2010; 105:2420-8.
6. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104:13780-5.
7. Cummings JH. Short chain fatty-acids in the human-colon. Gut 1981; 22:763-79.
8. Fooks LJ, Fuller R, Gibson GR. Prebiotics, probiotics and human gut microbiology. Int Dairy J 1999; 9:53-61.
9. Smith EA, Macfarlane GT. Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. J Appl Bacteriol 1996; 81:288-302.
10. Marchesi JR, Holmes E, Khan F., et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007; 6:546-51.
11. Le Gall G, Noor SO, Ridgway K, et al. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res 2011; 10:4208-18.
12. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1:514.
13. Vermeire S, Schreiber S, Sandborn W.J., et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010; 8:357-63.
14. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative-colitis-a randomized study. N Engl J Med 1987; 317:1625-9.
15. Shen B, Achkar JP, Lashner B.A., et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 2001; 121:261-7.
16. Matthys C, Pynaert I, De Keyzer W, et al. Validity and reproducibility of an adolescent web-based food frequency questionnaire. J Am Diet Assoc 2007; 107:605-10.
17. Hoebeeck LI, Rietzschel ER, Langlois M, et al. Diet and subclinical atherosclerosis. Eur J Clin Nutr 2011; 65:606-13.
18. Cade J, Thompson R, Burley V., et al. Development, validation and utilisation of food-frequency questionnaires-a review. Public Health Nutr 2002; 5:567-87.
19. De Preter V, Van Staeyen G, Esser D, et al. Development of a screening method to determine the pattern of fermentation metabolites in faecal samples using on-line purge-and-trap gas chromatographic-mass spectrometric analysis. J Chromatogr A 2009; 1216:1476-83.
20. De Preter V, Ghebretinsae AH, Abrahantes J.C., et al. Impact of the synbiotic combination of Lactobacillus casei shirota and oligofructose-enriched inulin on the fecal volatile metabolite profile in healthy subjects. Mol Nutr Food Res 2011; 55:714-22.
21. Williams HR, Cox IJ, Walker D.G., et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol 2009; 104:1435-44.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 1995; 57:289-300.
23. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140:1720-8.
24. Joossens M, Huys G, Cnockaert M., et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011; 60:631-7.
25. Mahowald MA, Rey FE, Seedorf H, et al. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci USA 2009; 106:5859-64.
26. Williams HRT, Cox IJ, Walker D.G., et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterology 2009; 104:1435-44.
27. Bjerrum JT, Nielsen OH, Hao F.H., et al. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res 2010; 9:954-62.
28. Hamer HM, De Preter V, Wndey K, et al. Functional analysis of colonic bacterial metabolism: relevant to health? Am J Physiol Gastrointest Liver Physiol 2012; 302: G1-9.
29. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134:577-94.
30. Machiels K, Joossens M, Sabino J., et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014; 63:1275-83.
31. Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl 1996; 216:132-48.
32. Roediger WEW, Duncan A, Kapaniris O., et al. Reducing sulfur-compounds of the colon impair colonocyte nutrition-implications for ulcerative-colitis. Gastroenterology 1993; 104:802-9.
33. Jorgensen J, Mortensen PB. Hydrogen sulfide and colonic epithelial metabolism-implications for ulcerative colitis. Dig Dis Sci 2001; 46:1722-32.
34. Segain JP, de la Bletiere DR, Bourreille A, et al. Butyrate inhibits inflammatory responses through NF kappa B inhibition: implications for Crohn's disease. Gut 2000; 47:397-403.
35. De Preter V, Arijs I, Windey K., et al. Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway. Inflamm Bowel Dis 2012; 18:1127-36.
36. Garner CE, Smith S, de Lacy Costello B, et al. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J 2007; 21:1675-88.
37. Jorgensen JR, Clausen MR, Mortensen PB. Oxidation of short and medium chain C2-C8 fatty acids in Sprague-Dawley rat colonocytes. Gut 1997; 40:400-5.
38. Hsiao CP, Siebert KJ. Modeling the inhibitory effects of organic acids on bacteria. Int J Food Microbiol 1999; 47:189-201.
39. Zentek J, Buchheit-Renko S, Manner K., et al. Intestinal concentrations of free and encapsulated dietary medium-chain fatty acids and effects on gastric microbial ecology and bacterial metabolic products in the digestive tract of piglets. Arch Anim Nutr 2012; 66:14-26.
40. Liberato MV, Nascimento AS, Ayers S.D., et al. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) gamma activators and Pan-PPAR partial agonists. PLoS ONE 2012; 7:e36297.
41. Calder PC. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 2008; 52:885-97.
42. Bassaganya-Riera J, Hontecillas R, Horne W.T., et al. Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease. Clin Nutr 2012; 31:721-7.
43. Bassaganya-Riera J, Viladomiu M, Pedragosa M., et al. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR gamma to suppress colitis. PLoS ONE 2012; 7:e31238.
44. Matsumoto M, Kibe R, Ooga T., et al. Impact of intestinal microbiota on intestinal luminal metabolome. Sci Rep 2012; 2:233.
45. Bone E, Tamm A, Hill M. Production of urinary phenols by gut bacteria and their possible role in causation of large bowel cancer. Am J Clin Nutr 1976; 29:1448-54.
46. Sokol H, Lay C, Seksik P., et al. Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis 2008; 14:858-67.
47. Blachier F, Davila AM, Mimoun S, et al. Luminal sulfide and large intestine mucosa: friend or foe? Amino Acids 2010; 39:335-47.
48. Jowett SL, Seal CJ, Pearce M.S., et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 2004; 53:1479-84.
49. Yamagishi K, Onuma K, Chiba Y., et al. Generation of gaseous sulfur-containing compounds in tumour tissue and suppression of gas diffusion as an antitumour treatment. Gut 2012; 61:554-61.
50. Cai WJ, Wang MJ, Ju L.H., et al. Hydrogen sulfide induces human colon cancer cell proliferation: role of Akt, ERK and p21. Cell Biol Int 2010; 34:565-72.
51. De Preter V, Arijs I, Windey K., et al. Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis. Inflamm Bowel Dis 2012; 18:2371-80.
52. Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 2011; 11:7.
53. Sabatini N, Perri E, Marsilio V An investigation on molecular partition of aroma compounds in fruit matrix and brine medium of fermented table olives. Innovative Food Sci Emerg Technol 2009; 10:621-6.
54. Geypens B, Claus D, Evenepoel P., et al. Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. Gut 1997; 41:70-6.
55. Salemans JM, Nagengast FM, Lubbers E.J., et al. Postoperative and long-term results of ileal pouch-anal anastomosis for ulcerative colitis and familial polyposis coli. Dig Dis Sci 1992; 37:1882-9.
56. Zella GC, Hait EJ, Glavan T, et al. Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis. Inflamm Bowel Dis 2011; 17:1092-100.
57. Miekisch W, Schubert JK, Vagts D.A., et al. Analysis of volatile disease markers in blood. Clin Chem 2001; 47:1053-60.
58. Salerno-Kennedy R, Cashman KD. Potential applications of breath isoprene as a biomarker in modern medicine: a concise overview. Wien Klin Wochenschr 2005; 117:180-6.
59. Pelli MA, Trovarelli G, Capodicasa E., et al. Breath alkanes determination in ulcerative colitis and Crohn's disease. Dis Colon Rectum 1999; 42:71-6.
60. Ahmed I, Greenwood R, Costello Bde L, et al. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS ONE 2013; 8:e58204.